Expansion of Safety-Lead in Sites for NRG Phase I Committee

The NRG Phase I Subcommittee is looking to expand the number of sites who can participate on the safety lead-in component of studies. Key considerations for being a safety lead-in site are

• the ability to enter patient safety data in real-time
• have the site physician member or physician delegate participate on the safety calls (currently scheduled for Friday afternoons at 3:30PM ET).

Please refer to the NRG Oncology Phase I Procedure Manual and NRG Oncology Phase I Member Application (also located on the DT Committee page of the NRG Oncology website).

For more information or to submit an application to become a safety lead-in site please contact:

Roisin O'Cearbhaill, MD, NRG Developmental Therapeutics Chair (ocearbhr@mskcc.org)

Russell Schilder, MD, NRG Phase I Chair (russell.schilder@jefferson.edu)

Stephanie Gaillard, MD PhD, NRG Phase I Co-Chair (stephanie.gaillard@jhmi.edu)

Responses requested by March 20, 2023